• Earlier this month, Neurocrine Biosciences reported new real-world survey data showing that adults with clinician-rated mild tardive dyskinesia treated with INGREZZA often experienced fewer involuntary movements and broad functional gains, many within four weeks.
• The findings, aligned with American Psychiatric Association guidance, suggest INGREZZA’s benefits may extend beyond symptom control to improvements in independence, daily activities and ability to work for patients with mild TD.
• We'll now examine how this new real-world evidence for INGREZZA, especially in mild tardive dyskinesia, could influence Neurocrine's investment narrative.

Outshine the giants: these 15 early-stage AI stocks could fund your retirement.

Neurocrine Biosciences Investment Narrative Recap

To own Neurocrine, you need to believe INGREZZA and CRENESSITY can sustain meaningful demand while the pipeline gradually broadens the story beyond a few core assets. The new real world data in mild tardive dyskinesia reinforces INGREZZA’s clinical and functional profile, but it does not materially change the near term catalyst focus or the key risks around pricing pressure, payer scrutiny, and product concentration.

The recent US$1.0 billion revolving credit facility is the most relevant parallel announcement, because it highlights Neurocrine’s decision to secure additional financial flexibility as it invests behind INGREZZA, CRENESSITY and late stage programs. While this financing does not directly affect the new TD data, it sits in the background of the same investment narrative, where execution on core franchises and careful balance sheet management will shape how catalysts and risks ultimately play out.

Yet even with encouraging INGREZZA data, investors should be aware of growing pricing and access pressure, especially as Medicare and large payers...

Neurocrine Biosciences' narrative projects $4.1 billion revenue and $1.0 billion earnings by 2029. This requires 13.0% yearly revenue growth and a $521.4 million earnings increase from $478.6 million today.

Uncover how Neurocrine Biosciences' forecasts yield a $186.45 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were assuming revenue might reach about US$5.8 billion and earnings US$1.8 billion by 2029, lean heavily on INGREZZA expanding into broader TD segments, while the new real world data and payer risks you have seen here could push that bullish story, and the more cautious one, in very different directions over time.

Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth just $186.45!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Neurocrine Biosciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.